Last $1.16 USD
Change Today 0.00 / 0.00%
Volume 1.2M
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:40 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$1.15
Previous Close
$1.16
Day High
$1.19
Day Low
$1.13
52 Week High
02/13/14 - $5.19
52 Week Low
10/13/14 - $1.07
Market Cap
176.8M
Average Volume 10 Days
2.1M
EPS TTM
$-0.63
Shares Outstanding
153.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company’s commercial product includes Zohydro, a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain. It also develops Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

114 Employees
Last Reported Date: 03/7/14
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Chief Executive Officer, Interim Chief Commer...
Total Annual Compensation: $449.3K
President and Director
Total Annual Compensation: $370.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 10:55 AM

Zogenix, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 10:55 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Ann D. Rhoads, Chief Financial Officer, Principal Accounting Officer, Executive Vice President, Treasurer and Secretary.

Zogenix, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 11:30 AM

Zogenix, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 11:30 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ann D. Rhoads, Chief Financial Officer, Principal Accounting Officer, Executive Vice President, Treasurer and Secretary, Roger L. Hawley, Chief Executive Officer, Interim Chief Commercial Officer and Director, Stephen J. Farr, President and Director.

Zogenix, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Zogenix, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenue was $8,797,000 against $7,168,000 reported last year. Loss from operations was $20,665,000 compared to $11,022,000 a year ago. Loss before income taxes was $12,780,000 compared to $10,852,000 a year ago. Net loss was $12,825,000, or $0.09 per basic and diluted share compared to $10,852,000 or $0.10 per basic and diluted share a year ago. Net loss adjusted for certain non-cash or non-recurring items was $20,773,000 or $0.15 per diluted share against $12,541,000 or $0.12 per diluted share reported last year. For the nine months, total revenue was $25,632,000 against $23,091,000 reported last year. Income from operations was $29,153,000 compared to loss from operations of $38,679,000 a year ago. Income before income taxes was $29,153,000 compared to loss before income taxes of $45,240,000 a year ago. Net income was $29,108,000, or $0.21 per basic and diluted share compared to net loss of $45,240,000 or $0.44 per basic and diluted share a year ago. Net loss adjusted for certain non-cash or non-recurring items was $76,438,000 or $0.54 per diluted share against $42,496,000 or $0.42 per diluted share reported last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $1.16 USD 0.00

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corium International Inc $5.75 USD +0.05
Eternity Healthcare Inc $0.05 USD 0.00
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.